The chief medical officer at ML Bio Solutions spoke about the advances in neuromuscular diseases such as limb girdle muscular dystrophy at the 2023 MDA Conference. [WATCH TIME: 3 minutes]
Videos
Drs Ahmed Zayed Obeidat and Mark S. Freedman share considerations for individualized therapy for the management of MS.
Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC, provides an overview of disease-modifying therapies for the treatment of multiple sclerosis.
The vice president of Health Economic and Outcomes Research at Acadia Pharmaceuticals discussed the ongoing challenges with lowering mortality in Parkinson disease, and the need to improve caregiver burden. [WATCH TIME: 4 minutes]
The director of the Center for Biologics Evaluation Research at the FDA provided an overview of the Keynote Address he gave at the 2023 Muscular Dystrophy Association Clinical and Scientific Conference. [WATCH TIME: 3 minutes]
The neurologist and migraine expert from NYU Langone Health shared her reactions to the recently approved zavegepant nasal spray (Zavzpret; Pfizer) for the treatment of migraine. [WATCH TIME: 5 minutes]
Neurology News Network for the week ending March 18, 2023. [WATCH TIME: 4 minutes]
The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
Expert neurologist highlights ongoing research in newer mechanisms of action and modes of delivery for treatments of Parkinson’s disease and OFF episodes.
Stuart Isaacson, MD, FAAN, evaluates the current treatment paradigm and highlights new, ‘on-demand’ medication for management of OFF episodes in Parkinson’s disease.
Stuart Isaacson, MD, FAAN, discusses the pharmacological basis of OFF episodes in patients with Parkinson’s disease.
The neurologist at Mayo Clinic, in Jacksonville, Florida, spoke about inebilizumab as a treatment for NMOSD and other autoimmune diseases, such as encephalitis, in the ExTINGUISH trial. [WATCH TIME: 3 minutes]
The vice president of Health Economics and Outcomes Research at Acadia Pharmaceuticals provided perspective on the mechanistic advantages of pimavanserin over atypical antipsychotics to treat Parkinson disease psychosis. [WATCH TIME: 2 minutes]
The director of the Comprehensive Epilepsy Center at NYU Langone discussed the importance of healthy eating habits and whether all individuals with epilepsy should consider dieting early in their life. [WATCH TIME: 4 minutes]
In a recent interview, the associate professor at Harvard Medical School spoke about patient-centered research in the advancing treatment for patients with NMOSD. [WATCH TIME: 5 minutes]
The vascular neurologist at Cleveland Clinic provided an overview of a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. [WATCH TIME: 3 minutes]
The neurologist and physician scientist at Washington University in St. Louis provided perspective on the need for additional studies assessing the long-term effects of dieting strategies in multiple sclerosis. [WATCH TIME: 3 minutes]
At the 2023 ACTRIMS, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary, spoke on the impact of researching T-Bet+ memory B cells for new therapies in multiple sclerosis. [WATCH TIME: 5 minutes]
The executive director of the Alliance for Headache Disorders Advocacy provided perspective on the preparation that goes into Headache on the Hill, and the parties involved in this process. [WATCH TIME: 5 minutes]
At the 2023 ACTRIMS Forum, the post-doctoral associate in the department of clinical neurosciences at the University of Calgary talked about the main findings he observed with B cell therapies in patients with MS. [WATCH TIME: 4 minutes]
The director of the Comprehensive Epilepsy Center at NYU Langone provided insight on a recently published study assessing the metabolic effects of short-term modified Atkins diet in patients with epilepsy. [WATCH TIME: 4 minutes]
Neurology News Network for the week ending March 11, 2023. [WATCH TIME: 3 minutes]
The associate professor at Harvard Medical School talked about the currently approved therapies and the state of care for patients with NMOSD from a clinician perspective. [WATCH TIME: 5 minutes]
Expert neurologist reviews manifestations of OFF episodes and their impact on the quality of life of patients with Parkinson’s Disease.
Stuart Isaacson, MD, FAAN, defines the terminology of OFF episodes in Parkinson’s disease and what “OFF” means from a clinical perspective.
The associate professor of neurology at Columbia University and medical consultant and care center director for MDA offered his insight into the latest progress in ALS treatment and some of what will be discussed at the upcoming MDA Clinical & Scientific Conference.
The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed the potential for new therapies that target genetically mutated forms of Parkinson disease. [WATCH TIME: 3 minutes]
The clinical research director of the UCSF Multiple Sclerosis Center spoke about the barriers in accessing proven therapies for NMOSD at the 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
The associate director of the Multiple Sclerosis & Neuromyelitis Optica Unit at Massachusetts General Hospital discussed the ways employers and clinicians can alleviate work hardships experienced by patients with NMOSD. [WATCH TIME: 3 minutes]
The clinical assistant professor of neurology at Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, New York, talked about her presentation on Evusheld at the 2023 ACTRIMS Forum. [WATCH TIME: 5 minutes]
Advertisement
Advertisement
